The US vaccines firm Inviragen has started off the new year on the right foot by meeting one of the main goals for its cell cultured Japanese encephalitis (JE) vaccine: to partner the program with a local manufacturer in an endemic region.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?